Papers
2
Total Citations
167
H-Index
2
About
E. David Crawford is a towering figure in urologic oncology, whose career has been defined by landmark contributions to the treatment and understanding of prostate cancer. His research has fundamentally shaped how clinicians approach both localized and advanced disease. A central focus of his work has been the optimization of therapeutic strategies, particularly through rigorous clinical trials. He is renowned for his leadership in the Southwest Oncology Group (SWOG), where he spearheaded pivotal studies that have altered standard practice. For instance, his work on neoadjuvant therapy before radical prostatectomy for high-risk T3/T4 prostate cancer, detailed in the SWOG 9109 trial, provided crucial long-term follow-up data on this aggressive approach, influencing surgical and oncologic planning. Furthermore, Crawford’s investigations into the impact of prior local treatment on the progression to metastatic disease have been highly influential, with his 2002 paper on the subject accumulating over 100 citations. This work highlighted critical patterns in disease recurrence and management. Through these and other contributions, Dr. Crawford has not only advanced scientific knowledge but also directly improved patient outcomes, cementing his legacy as a pioneer in the fight against prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2